Mexico Medical Device Regulation
RAPath Mexico is a plain-English reference guide to medical device regulation in Mexico, covering the full device lifecycle under COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) — Mexico's federal health authority.
COFEPRIS operates as a division of Mexico's Ministry of Health (Secretaría de Salud / SSA). It governs device classification, market authorisation, quality system requirements, post-market surveillance, and enforcement for all medical devices placed on the Mexican market.
Regulatory Pathway Map
Click a phase to expand — each card links to the relevant section of this guide.
What this site covers
| Section | What you'll find |
|---|---|
| Getting Started | Framework overview, who needs to comply, DIGIPRiS portal |
| Device Classification | Class I · II · III, exemption annexes, IVD & SaMD |
| Pre-Market | Standard route, equivalency route, dossier, timelines |
| Mexico Registration Holder | MRH obligations, appointing, changing holders |
| Post-Market | Technovigilance, NOM-240, renewals, labelling |
| Quality System (NOM-241) | GMP requirements, ISO 13485 equivalency, inspections |
| Legislation & NOMs | Ley General de Salud, Reglamento Insumos, NOM tracker |
| Digital Health & SaMD | Software, AI/ML, mobile health apps |
| Special Access | Compassionate use, clinical investigations |
| International | IMDRF, PANDRH, MDSAP, multi-market strategy |
| Resources | Links, DIGIPRiS guide, fees, forms |
The regulatory framework at a glance
Mexico's medical device regulatory system rests on three tiers:
- Ley General de Salud (General Health Law) — the primary federal legislation establishing COFEPRIS's mandate and the requirement for sanitary registration.
- Reglamento de Insumos para la Salud (Health Supplies Regulation) — detailed requirements for classification, registration, GMP, and post-market obligations.
- Normas Oficiales Mexicanas (NOMs) — mandatory technical standards covering GMP (NOM-241), labelling (NOM-137), and technovigilance (NOM-240).
Key 2024–2025 reforms
Mexico's regulatory framework has undergone significant modernisation:
- September 2025 — Abbreviated (Equivalency) Route formally expanded to all IMDRF and MDSAP member authority approvals (FDA, Health Canada, CE Mark, TGA and more), with a 30-working-day target review. This expansion simplifies market entry for devices already approved by recognized international authorities, reducing local dossier requirements and review timelines. See Equivalency Route.
- May 2025 — NOM-137-SSA1-2025 (labelling) published; enters force May 2027. Introduces updated label elements including intended use, manufacturing date, and adverse incident instructions. See Labelling — NOM-137.
- July 2025 — New classification decree replaces 2011/2014 exemption agreements, introducing updated Annexes 1–3. See Device Classification.
- April 2025 — NOM-241-SSA1-2025 (GMP) entered into effect, replacing the 2021 version. See NOM-241 Overview.
- January 2026 — Subsequent registration renewals now eligible for periods of up to 10 years.
How to use this site
Each section follows the same structure: an overview page explains the concept and its legal basis, followed by topic pages with practical detail. Every page links back to the relevant NOM, Ley General de Salud article, or COFEPRIS decree.
This site is a regulatory reference resource, not legal or regulatory affairs advice. Regulations change. Always verify requirements against the current text of the relevant NOM or COFEPRIS decree. For device-specific guidance, consult a qualified regulatory affairs professional.
Part of the RAPath suite — medical device regulatory reference.